Creabilis SA

A clinical stage European biotechnology company addressing unmet medical needs in serious dermatological and inflammatory diseases.

CT327 - TrkA Kinase Modulation
CT637 - Inflammatory & auto-immune disorders
CT340 - LSE modified kinase inhibitor
LSE technology - Creating new chemical entities ideal for topical application

Details Contacts

A novel topically
applied TrkA kinase
inhibitor.

A new biological approach to the treatment of significant inflammatory conditions.

LSE modified kinase inhibitor.

Creating new chemical
entities ideal for
topical application.

Nov01

Creabilis CEO interviewed by EP Vantage.
Read more »

Oct25

Creabilis establishes operations in the UK.
Read more »

Oct04

Creabilis Raises �15.0M ($20M) in Series B Fundraising Round.
Read more »